Retirement Systems of Alabama raised its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) by 1.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 95,110 shares of the life sciences company’s stock after acquiring an additional 926 shares during the period. Retirement Systems of Alabama owned approximately 0.11% of Integra LifeSciences worth $4,029,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also recently modified their holdings of IART. Texas Permanent School Fund raised its stake in Integra LifeSciences by 0.4% during the second quarter. Texas Permanent School Fund now owns 51,833 shares of the life sciences company’s stock valued at $2,801,000 after purchasing an additional 191 shares in the last quarter. Money Concepts Capital Corp lifted its holdings in shares of Integra LifeSciences by 2.3% in the 3rd quarter. Money Concepts Capital Corp now owns 9,095 shares of the life sciences company’s stock valued at $385,000 after acquiring an additional 205 shares during the last quarter. Oregon Public Employees Retirement Fund grew its position in Integra LifeSciences by 1.1% in the third quarter. Oregon Public Employees Retirement Fund now owns 21,216 shares of the life sciences company’s stock worth $899,000 after acquiring an additional 227 shares in the last quarter. Inspire Investing LLC increased its stake in Integra LifeSciences by 6.9% during the second quarter. Inspire Investing LLC now owns 3,890 shares of the life sciences company’s stock worth $210,000 after acquiring an additional 252 shares during the last quarter. Finally, AMG National Trust Bank raised its position in Integra LifeSciences by 1.9% during the third quarter. AMG National Trust Bank now owns 15,993 shares of the life sciences company’s stock valued at $677,000 after purchasing an additional 301 shares during the period. 87.60% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the company. TheStreet raised Integra LifeSciences from a “c+” rating to a “b-” rating in a research report on Tuesday, December 27th. Jefferies Financial Group initiated coverage on shares of Integra LifeSciences in a research note on Tuesday, October 11th. They issued a “hold” rating and a $48.00 price objective for the company. Morgan Stanley upped their target price on Integra LifeSciences from $50.00 to $59.00 and gave the company an “equal weight” rating in a research note on Friday, January 6th. Citigroup raised their price target on Integra LifeSciences from $50.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, December 12th. Finally, JMP Securities cut their price objective on Integra LifeSciences from $85.00 to $75.00 and set a “market outperform” rating on the stock in a research report on Thursday, October 27th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences currently has an average rating of “Hold” and an average target price of $58.33.
Integra LifeSciences Price Performance
IART opened at $58.57 on Thursday. The firm has a market capitalization of $4.89 billion, a PE ratio of 28.43, a price-to-earnings-growth ratio of 1.60 and a beta of 1.14. The business’s 50-day moving average is $56.34 and its two-hundred day moving average is $51.90. Integra LifeSciences Holdings Co. has a 1 year low of $40.67 and a 1 year high of $68.29. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.93 and a quick ratio of 2.91.
Integra LifeSciences Profile
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.
See Also
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating).
Receive News & Ratings for Integra LifeSciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Integra LifeSciences and related companies with MarketBeat.com’s FREE daily email newsletter.
